Results 11 to 20 of about 12,450 (234)

KSNM60: The History of Radiopharmaceutical Sciences in Korea. [PDF]

Nucl Med Mol Imaging, 2022
A number of researchers in Korea have tried to set-up the production of radionuclides and develop new radiopharmaceuticals for several decades. Thanks to their 60-year endeavor to advance the field of radiopharmaceutical sciences, now we have a lot of research units and facilities in Korea.
Yoo RJ, Lee YS, Lee KC, Kim DW, Kim DY, Choe YS, Jeong JM.   +6 more
europepmc   +4 more sources

Recent advances and impending challenges for the radiopharmaceutical sciences in oncology. [PDF]

Lancet Oncol
This paper is the first of a Series on theranostics that summarises the current landscape of the radiopharmaceutical sciences as they pertain to oncology. In this Series paper, we describe exciting developments in radiochemistry and the production of radionuclides, the development and translation of theranostics, and the application of artificial ...
Lapi SE, Scott PJH, Scott AM, Windhorst AD, Zeglis BM, Abdel-Wahab M, Baum RP, Buatti JM, Giammarile F, Kiess AP, Jalilian A, Knoll P, Korde A, Kunikowska J, Lee ST, Paez D, Urbain JL, Zhang J, Lewis JS.   +18 more
europepmc   +6 more sources

Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics. [PDF]

Lancet Oncol
Although the promise of radionuclides for the diagnosis and treatment of disease was recognised soon after the discovery of radioactivity in the late 19th century, the systematic use of radionuclides in medicine only gradually increased over the subsequent hundred years.
Scott AM, Zeglis BM, Lapi SE, Scott PJH, Windhorst AD, Abdel-Wahab M, Giammarile F, Piaez D, Jalilian A, Knoll P, Korde A, Vichare S, Ayati N, Lee ST, Lyashchenko SK, Zhang J, Urbain JL, Lewis JS.   +17 more
europepmc   +4 more sources

How green are radiopharmaceutical sciences? [PDF]

Nuclear Medicine and Biology
The rapid growth of radiopharmaceutical sciences, driven by regulatory approvals of theranostic agents and the expanding role of PET imaging, underscores the need for sustainable and green practices. While radiopharmaceuticals offer high precision and targeted therapy with minimal systemic toxicity, the field faces challenges related to increasing ...
Peter J H Scott, Matthias M Herth, Sarah Spreckelmeyer   +2 more
exaly   +4 more sources

Status of the 'consensus nomenclature rules in radiopharmaceutical sciences' initiative. [PDF]

Nucl Med Biol, 2019
Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.   +10 more
europepmc   +5 more sources

Nuclear medicine procedures and the evaluation of male sexual organs: a short review [PDF]

, 2008
Sexuality consists of three aspects that are interrelated and inseparable, biological, physiological and social. The biological aspect considers the individual's capability to give and to receive pleasure.
Adenilson de Souza da Fonseca, Bernardo-Filho M., Beutel M. E., Bouchelouche K., Chaffanjon P. C., Choe W., Dennerstein L., Fanti S., Ganjoo K. N., Gerber G., Halac M., Hatzimouratidis H., Jana S., Kevin Carter, Kim C. K., Kolodny R. C., Kotzerke J., Kotzerke J., Kumar V., Lange P. H., Mario Bernardo-Filho, Masters W. H., Orhan I., Perkins A., Perkins A., Ravizzini G., Roivainen A., Ryu J., Saha G., Sebastião David Santos-Filho, Shen Y. Y., Sotiris Missailidis, Stelzner F., Sumich A. L., Timmermans L., Tóth G., Valdés Olmos R. A., Warren G. P., Willan B. D., Zuckier L. S.   +39 more
core   +4 more sources

Special Issue “Targets, Tracers and Translation Novel Radiopharmaceuticals Boost Nuclear Medicine”

Pharmaceuticals, 2019
This is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences [...]
Gerald Reischl
doaj   +1 more source

Evaluation of Actinium-225 Labeled Minigastrin Analogue [²²⁵Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy

Pharmaceutics, 2020
The overexpression of cholecystokinin B receptor (CCKBR) in human cancers led to the development of radiolabeled minigastrin analogues for targeted radionuclide therapy, which aims to deliver cytotoxic radiation specifically to cancer cells.
Yun Qin, Stefan Imobersteg, Alain Blanc, Stephan Frank, Roger Schibli, Martin P. Béhé, Michal Grzmil   +6 more
doaj   +1 more source

Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma

BMC Cancer, 2018
Background Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer.
Dennis Lindenblatt, Nastassja Terraneo, Giovanni Pellegrini, Susan Cohrs, Philipp René Spycher, David Vukovic, Martin Béhé, Roger Schibli, Jürgen Grünberg   +8 more
doaj   +1 more source

Neuroimaging with Radiopharmaceuticals Targeting the Glutamatergic System

CHIMIA, 2020
Radiopharmacy at ETH has worked on the development of novel PET tracers for neuro-, cardiac- and tumor imaging for many years. In this paper, our efforts on targeting the glutamatergic system of the metabotropic glutamate receptor subtype 5 (mGluR5) and ...
Linjing Mu, Stefanie D. Kramer, Hazem Ahmed, Stefan Gruber, Susanne Geistlich, Roger Schibli, Simon M. Ametamey   +6 more
doaj   +1 more source